rs137853334 — HNF4A HNF4A MODY1 Variant

Pathogenic nonsense variant in HNF4A causing MODY1 — a progressive, autosomal dominant monogenic diabetes with neonatal hypoglycemia and sulfonylurea sensitivity

See your personal result for HNF4A

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Molecular Switch That Writes Your Diabetes Timeline

HNF4A (Hepatocyte Nuclear Factor 4 Alpha) is a master transcription factor that controls hundreds of genes in pancreatic beta cells and the liver. Unlike the common polygenic variants that nudge diabetes risk by a few percent, a pathogenic variant in HNF4A rewrites your entire metabolic trajectory11 rewrites your entire metabolic trajectory
HNF4A sits at the top of a transcription factor cascade: it regulates HNF1A, which regulates genes needed for glucose-stimulated insulin secretion. This is MODY1 — Maturity-Onset Diabetes of the Young, type 1 — and it follows a trajectory unlike any common form of diabetes: paradoxical hyperinsulinism at birth, followed by progressive insulinopenia in adulthood.

The Mechanism

The c.763C>T variant introduces a premature stop codon at position 277 (p.Gln277Ter), truncating the protein and deleting the C-terminal 187 amino acids. The truncated protein loses its transcriptional transactivation activity — it cannot dimerize, cannot bind DNA, and cannot activate target genes22 cannot dimerize, cannot bind DNA, and cannot activate target genes
Stoffel & Duncan 1997 showed the Q268X truncated protein had no DNA-binding activity in reporter assays and failed to transactivate HNF4A target genes. Because HNF4A is required for normal transcription of genes driving glucose-stimulated insulin secretion in pancreatic beta cells, haploinsufficiency — one functional copy instead of two — causes progressive loss of beta-cell response to glucose.

The temporal paradox is striking: in the fetal and neonatal period, the same mutation causes excessive insulin secretion33 same mutation causes excessive insulin secretion
Mice with beta-cell deletion of Hnf4a show hyperinsulinism in utero and hyperinsulinemic hypoglycemia at birth, confirming the mechanism, producing macrosomia and neonatal hypoglycemia. Over years, beta-cell capacity declines progressively, and insulinopenic diabetes emerges — usually in the second or third decade of life.

The Evidence

The landmark 1996 study by Yamagata et al.44 landmark 1996 study by Yamagata et al.
Yamagata K et al. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature, 1996 identified HNF4A as the gene responsible for MODY1 in the historic RW pedigree — a six-generation Michigan family with 74 affected members studied prospectively since 1958. The Q268X mutation (equivalent to Q277X on current reference transcripts) was the founding pathogenic variant in this family.

The neonatal phenotype was quantified by Pearson et al. in 107 HNF4A mutation carriers55 Pearson et al. in 107 HNF4A mutation carriers
Pearson ER et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLOS Medicine, 2007: 56% of carriers were macrosomic (mean birth weight 4,450 g), a median 790 g heavier than unaffected siblings (p<0.001). Transient neonatal hypoglycemia occurred in 15% of carriers — versus none of the unaffected family members.

For treatment, Crowley et al. 202566 Crowley et al. 2025
Crowley MT et al. Sulphonylurea efficacy and end-organ outcomes in the management of HNF4A-MODY. Diabetic Medicine, 2025 followed HNF4A-MODY patients on sulfonylurea monotherapy for six years: 51.6% achieved significant HbA1c reduction (p=0.045), with responders maintaining HbA1c at 45 mmol/mol (6.3%) compared to 58 mmol/mol (7.5%) before treatment. Responders tended to be younger with shorter disease duration — arguing for early diagnosis and early initiation.

Mirshahi et al. 202277 Mirshahi et al. 2022
Mirshahi UL et al. Reduced penetrance of MODY-associated HNF1A/HNF4A variants but not GCK variants in clinically unselected cohorts. Am J Hum Genet, 2022 found that penetrance varies dramatically by discovery context: 98% in clinical referral cohorts by age 40, but only 5–17% in population health system cohorts. This means that an HNF4A pathogenic variant found incidentally in a healthy adult carries lower disease probability than the same variant found in a referred diabetic patient — context matters for counseling.

Practical Actions

The most important single thing a carrier can do: obtain a definitive genetic diagnosis and discuss transition to sulfonylurea therapy with a specialist in monogenic diabetes. Sulfonylureas bypass the impaired glucose-stimulated insulin secretion by directly stimulating the KATP channel in beta cells — they work where the genetic defect cannot. HNF4A-MODY patients often respond dramatically better to low-dose sulfonylurea than to insulin.

Pregnancy requires special management: glibenclamide crosses the placenta at ~70% of maternal levels, amplifying the genetic tendency toward macrosomia and neonatal hypoglycemia. Women on sulfonylurea should transition to insulin before conception or by the second trimester. Neonatal glucose monitoring is mandatory for all newborns of HNF4A carriers, regardless of the father's or mother's glycemic control.

Family screening is strongly indicated: with 50% inheritance probability and high penetrance in the clinical setting, first-degree relatives of a confirmed MODY1 carrier should all have genetic testing offered.

Interactions

HNF4A sits directly upstream of HNF1A (MODY3) in the transcription factor hierarchy — HNF4A activates HNF1A transcription, and HNF1A in turn regulates many of the same beta-cell function genes. Rare patients carry pathogenic variants in both HNF4A and HNF1A (digenic MODY), presenting with earlier onset and more severe disease than either mutation alone. If a first-degree relative has a known HNF1A pathogenic variant, combined panel testing covering HNF4A, HNF1A, GCK, HNF1B, and other MODY genes is preferred over single-gene testing.

Drug Interactions

sulfonylureas (gliclazide, glipizide, glibenclamide, tolbutamide) dose_adjustment literature
glibenclamide (pregnancy) contraindicated literature

Genotype Interpretations

What each possible genotype means for this variant.

CC No MODY1 Variant Normal

No HNF4A MODY1 variant detected

You do not carry the rs137853334 pathogenic variant in HNF4A. This means you are not at increased risk for HNF4A-MODY1 from this specific variant. MODY1 is rare — pathogenic HNF4A variants are present in approximately 1 in 7,000 individuals across the population. The overwhelming majority of people share your CC genotype.

Note that other pathogenic variants in HNF4A (not captured by this position) can also cause MODY1; a negative result here does not rule out HNF4A-MODY if clinical features are suggestive.

CT MODY1 Carrier High Risk

Pathogenic HNF4A variant — MODY1 diagnosis likely if not already established

The biphasic phenotype of HNF4A mutations is unique in diabetes genetics. In utero and immediately after birth, haploinsufficiency of HNF4A paradoxically increases insulin secretion, causing 56% macrosomia rates (median birth weight 4,450 g, +790 g versus unaffected siblings) and transient hyperinsulinemic hypoglycemia in 15% of carriers (Pearson et al. 2007, PMID 17407387). The mechanism for this neonatal hyperinsulinism is not fully understood, but the pattern is well-documented across multiple large pedigrees.

Over years, the progressive loss of HNF4A transcriptional function leads to declining glucose-stimulated insulin secretion. Diabetes typically appears in the second to third decade but can present as early as childhood. The condition worsens with age and with weight gain; maintaining a healthy weight is associated with prolonged sulfonylurea monotherapy response.

Sulfonylurea response rate in HNF4A-MODY: 51.6% achieve significant HbA1c reduction on monotherapy at 6 years (Crowley et al. 2025, PMID 40954556). Those who do not achieve adequate control on sulfonylurea alone often benefit from adjunctive GLP-1 receptor agonists or SGLT2 inhibitors.

Penetrance in population health system cohorts (i.e., incidentally discovered) is substantially lower (5–17% by age 40) than in clinically referred cohorts (98%), suggesting phenotypic modifiers play a role. However, the variant's ClinGen Pathogenic classification is robust — carriers should be monitored regardless of current glycemic status.

TT Homozygous MODY1 Homozygous

Extremely rare homozygous state — severe HNF4A loss of function expected

You appear to carry two copies of the rs137853334 pathogenic variant. This homozygous state is extraordinarily rare — the T allele has zero observed frequency in all population databases (gnomAD, ALFA), and no homozygous individuals have been documented in the published MODY1 literature. This result warrants urgent clinical confirmation and specialist review.

If the result is confirmed accurate, complete biallelic loss of HNF4A function would be expected to cause severe early-onset diabetes and potentially additional developmental abnormalities, as HNF4A is critical for liver, kidney, and intestinal development in addition to the pancreas. This finding should be treated as an urgent clinical concern.